Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
Antiviral Res. 2022 Feb;198:105252. doi: 10.1016/j.antiviral.2022.105252. Epub 2022 Jan 24.
Antiviral Res. 2022.
PMID: 35085683
Free PMC article.